New Zealand shares fell on the first day of the month in a muted trading session after institutional investors staked out positions yesterday. Contact Energy and Summerset Group Holdings declined.
The S&P/NZX50 Index dropped 58.14 points, or 0.7 percent, to 8,383.87. Within the index, 34 stocks fell, eight rose, and eight were unchanged. Turnover was $96 million.
The benchmark index gave up some of yesterday's gains when it jumped 1.7 percent on turnover of more than $200 million. That month-end positioning by large investors coincided with Xero's final day of trading on NZX to become solely listed on the Australian Securities Exchange.
"It was the end of the month as well, and that's often when you get the big portfolio trades which influence outcomes over a day, settling positions for the end of a period or whatever," said Greg Easton, investment adviser at Craigs Investment Partners. "Today's so quiet, and that probably does reflect that a lot of that positioning was completed yesterday."
The worst performer was Contact Energy, down 2.3 percent to $5.46, with Summerset falling 2.1 percent to $5.63.
"A lot of the gains yesterday happened towards the end of the day's trade, which really does indicate it was that funds management end of the market dictating things," Easton said.
The stocks that gained the most yesterday faced the biggest losses today, with SkyCity Entertainment Group down 1.9 percent to $4.07, paring some of Wednesday's 4.3 percent gain. Air New Zealand dropped 1 percent to $3.05 having gained 3.7 percent yesterday, and Sky Network Television dropped 1 percent to $2.88 after it advanced 3.6 percent previously.
The best performer today was Fonterra Shareholders' Fund, which rose 1.5 percent to $2.69, while Mainfreight gained 1 percent to $26.01.
Outside the benchmark index, Pacific Edge shares rose 12 percent to 43 cents after the cancer diagnostics firm signed its first commercial deal to supply its suite of Cxbladder tests in Singapore.
The Dunedin-based company said it reached a commercial agreement with a unit of Raffles Medical Group to use the bladder cancer tests in Singapore. Under the deal, the Raffles unit will coordinate specimen collection, shipping and reporting of Cxbladder tests for the medical firm's patients in the Asian city.
"They've signed heaps of these sorts of agreements in the States where we've been looking to see the revenue flow from, but it really hasn't started so while this is possibly good news it is going to be a long time before revenues really flow," Easton said. "It's good that they're out there selling it anyway, and the product obviously has a market."
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Russell McVeagh incident highlights complications of corporate sponsorship
- Sir Ralph explains why he didn’t listen but NZSA calls it a failure of governance
- Could Nikki Kaye lead National one day? A wee problem
- Poor facing double whammy when road congestion pricing gets off the ground
- The highest paid directors
Most listened to
- Ian Apperley goes cold turkey on social media, and claims he's now a better man
- Auckland Airport's CEO Adrian Littlewood explains the impact of price changes on revenue
- Competition lawyer Michael Wigley supports the Criminalisation of Cartels Amendment Bill
- Roadtrippers deal is a gamechanger, says Tourism Holdings CEO Grant Webster
- The sub-contracting model is killing the New Zealand construction industry, says E tū's Ron Angel
- NBR Radio: The best interviews – updated daily, with Grant Walker